Multiple myeloma (MM) treatment has changed tremendously, with significant improvement in patient out-comes. One group with a suboptimal benefit is patients with high-risk cytogenetics, as tested by ...

Global Cytogenetic Systems Market demand is anticipated to be valued at US$ 1,688.5 Million in 2022, forecast to grow at a CAGR of 8.5% to be valued at US$ 5,327.8 Million from 2022 to 2032. Growth is ...

The global demand for cytogenetic systems is set to experience substantial growth, with a market valuation projected to rise from USD 1,688.5 million in 2022 to USD 5,327.8 million by 2032. This 11.0% ...

Income and location divide in myeloma outcomes: A call for equitable care. Response rate to initial line of therapy and overall survival from diagnosis among patients tested for HR secondary CA both ...

The global molecular cytogenetics market is projected to reach USD 1.43 billion by 2030 from USD 1.02 billion in 2025 at a CAGR of 7.1% from 2025 to 2030. The surge is attributed to rapidly increasing ...

REDDING, Calif., March 28, 2025 /PRNewswire/ -- According to a new market research report titled 'Cytogenetics Market Size, Share, Forecast, & Trends Analysis by Product (Instruments, Consumables, ...

Thermo Fisher Scientific Inc., announced that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ Chromosomal Analysis Suite (ChAS) Dx software now comply with In Vitro Diagnostic ...

The demand for personalized medicine is a major factor propelling market expansion, with cytogenetic techniques playing a critical role in oncology, prenatal testing, and rare disease diagnosis.

The genetic testing market accounted for $ 12,682 million in 2019, and is expected to reach $ 21,260 million by 2027, registering a CAGR of 10.1% from 2020 to 2027. The global genetic testing market ...